Shibin Zhou

List of Publications by Year in Descending Order

33 papers	16,728 citations	21 h-index	37 g-index
37 ext. papers	21,080 ext. citations	17.6 avg, IF	6.17 L-index

#	Paper	IF	Citations
33	TCR-mimic bispecific antibodies to target the HIV-1 reservoir.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2123406119	11.5	0
32	Bispecific antibodies targeting mutant neoantigens. *Science Immunology*, **2021**, 6,	28	42
31	Targeting loss of heterozygosity for cancer-specific immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	14
30	TCR chain-directed bispecific antibodies for the treatment of T cell cancers. *Science Translational Medicine*, **2021**, 13,	17.5	10
29	Targeting a neoantigen derived from a common mutation. *Science*, **2021**, 371,	33.3	68
28	Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. *Journal of Clinical Investigation*, **2021**, 131,	15.9	19
27	Targeting public neoantigens for cancer immunotherapy. *Nature Cancer*, **2021**, 2, 487-497	15.4	10
26	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. *ELife*, **2021**, 10,	8.9	7
25	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. *Nature*, **2021**, 596, 126-132	50.4	40
24	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. *Nature Communications*, **2021**, 12, 5271	17.4	5
23	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. *Science*, **2020**, 369,	33.3	149
22	Preventing cytokine storm syndrome in COVID-19 using 1 adrenergic receptor antagonists. *Journal of Clinical Investigation*, **2020**, 130, 3345-3347	15.9	69
21	Applications of liquid biopsies for cancer. *Science Translational Medicine*, **2019**, 11,	17.5	97
20	CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. *Quantitative Imaging in Medicine and Surgery*, **2019**, 9, 1579-1591	3.6	11
19	Direct Detection and Quantification of Neoantigens. *Cancer Immunology Research*, **2019**, 7, 1748-1754	12.5	21
18	CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. *Magnetic Resonance in Medicine*, **2019**, 82, 1471-1479	4.4	12
17	An engineered antibody fragment targeting mutant catenin via major histocompatibility complex I neoantigen presentation. *Journal of Biological Chemistry*, **2019**, 294, 19322-19334	5.4	8

16	Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science*, **2018**, 359, 926-930	33.3	1204
15	Characterization of tumor vascular permeability using natural dextrans and CEST MRI. *Magnetic Resonance in Medicine*, **2018**, 79, 1001-1009	4.4	26
14	Tumour-targeting bacteria engineered to fight cancer. *Nature Reviews Cancer*, **2018**, 18, 727-743	31.3	196
13	Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. *Nature*, **2018**, 564, 273-277	50.4	116
12	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, **2017**, 357, 409-413	333	3274
11	CEST theranostics: label-free MR imaging of anticancer drugs. *Oncotarget*, **2016**, 7, 6369-78	3.3	36
10	Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9967-72	11.5	27
9	Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. *ACS Nano*, **2015**, 9, 6861-71	16.7	89
8	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *New England Journal of Medicine*, **2015**, 372, 2509-20	59.2	5560
7	Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. *Oncotarget*, **2015**, 6, 5536-46	3.3	46
6	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 11774-9	11.5	426
5	A diaCEST MRI approach for monitoring liposomal accumulation in tumors. *Journal of Controlled Release*, **2014**, 180, 51-9	11.7	47
4	Cancer genome landscapes. *Science*, **2013**, 339, 1546-58	33.3	5058
3	A robust approach to enhance tumor-selective accumulation of nanoparticles. *Oncotarget*, **2011**, 2, 59-68	3.3	35
2	Combination therapy with bacteria and angiogenesis inhibitors: strangling cancer without mercy. *Cancer Biology and Therapy*, **2005**, 4, 846-7	4.6	3
1	Combination bacteriolytic cancer therapy: Attacking cancer from inside out. *Discovery Medicine*, **2004**, 4, 33-7	2.5	2